系统性硬化症患者健康评估问卷-残疾指数、患者报告结局测量信息系统-29简表2.0版各领域及患者健康问卷-8的最小可检测变化:硬皮病患者为中心干预网络队列横断面研究
该研究基于硬皮病患者为中心干预网络队列2571例系统性硬化症患者,估算HAQ-DI、PROMIS-29v2.0七个领域及PHQ-8的MDC95与MDC90,并比较年龄、性别和亚型亚组。MDC95估计精确且各亚组间无实质差异。
要点
- HAQ-DI的MDC95为0.41分(95%CI 0.40-0.42),MDC90未在摘要中给出具体数值。
- PROMIS-29v2.0七个领域的MDC95介于4.88分至9.02分之间,PHQ-8的MDC95为5.16分(95%CI 5.06-5.26)。
- 各年龄、性别和系统性硬化症亚组间MDC95估计无实质差异。
核心结论
- MDC95和MDC90估计精确,且在年龄、性别和系统性硬化症亚型组间相似。
- HAQ-DI的MDC95和MDC90 substantially大于既往数项小研究估计的HAQ-DI最小重要差异。
- 所有测量的最小重要差异应在大样本研究中采用锚定法进行评估(作者建议)。
研究设计与样本
- 硬皮病患者为中心干预网络队列的横断面研究,纳入2571例系统性硬化症患者,基线评估时间为2014年4月至2023年8月。
- 采用百分位自举法重采样1000次生成95%置信区间,估算MDC95和MDC90,并按年龄、性别和系统性硬化症亚型比较MDC估计。
主要发现
- 共纳入2571例参与者,其中女性2241例(87%),弥漫型系统性硬化症976例(38%);平均(±标准差)年龄54.9(±12.7)岁,自首个非雷诺现象症状起病病程10.8(±8.7)年。
- HAQ-DI的MDC95估计为0.41分(95%CI 0.40-0.42)。
- PROMIS-29v2.0七个领域的MDC95估计介于4.88分(95%CI 4.72-5.05)至9.02分(95%CI 8.80-9.23)之间。
- PHQ-8的MDC95估计为5.16分(95%CI 5.06-5.26)。
- MDC95估计在各亚组间无实质差异。
关键数值与推荐
- HAQ-DI的MDC95为0.41分(95%CI 0.40-0.42)。
- PROMIS-29v2.0七个领域的MDC95介于4.88分(95%CI 4.72-5.05)至9.02分(95%CI 8.80-9.23)。
- PHQ-8的MDC95为5.16分(95%CI 5.06-5.26)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出HAQ-DI的MDC95和MDC90 substantially大于既往数项小研究估计的HAQ-DI最小重要差异。
- 原文结论指出所有测量的最小重要差异应在大样本研究中采用锚定法进行评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis (SSc) is a rare, chronic autoimmune disorder associated with disability, diminished physical function, fatigue, pain, and mental health concerns. We assessed minimal detectable changes (MDCs) of the Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient-Reported Outcomes Measurement Information System-29 Profile version 2.0 (PROMIS-29v2.0) domains, and Patient Health Questionnaire (PHQ)-8 in people with SSc. METHODS: Scleroderma Patient-Centered Intervention Network Cohort participants completed the HAQ-DI, PROMIS-29v2.0 domains, and PHQ-8 at baseline assessments from April 2014 until August 2023. We estimated MDC95 (smallest change that can be detected with 95% certainty) and MDC90 (smallest change that can be detected with 90% certainty) with 95% confidence intervals (CIs) generated via the percentile bootstrapping method resampling 1,000 times. We compared MDC estimates by age, sex, and SSc subtype. RESULTS: A total of 2,571 participants were included. Most were female (n = 2,241; 87%), and 38% (n = 976) had diffuse SSc. Mean (±SD) age was 54.9 (±12.7) years and duration since onset of first non-Raynaud phenomenon symptom was 10.8 (±8.7) years. MDC95 estimate was 0.41 points (95% CI 0.40-0.42) for the HAQ-DI, between 4.88 points (95% CI 4.72-5.05) and 9.02 points (95% CI 8.80-9.23) for the seven PROMIS-29v2.0 domains, and 5.16 points (95% CI 5.06-5.26) for the PHQ-8. MDC95 estimates were not materially different across subgroups. CONCLUSION: MDC95 and MDC90 estimates were precise and similar across age, sex, and SSc subtype groups. HAQ-DI MDC95 and MDC90 were substantially larger than previous estimates of HAQ-DI minimal important difference from several small studies. Minimally important differences of all measures should be evaluated in large studies using anchor-based methods.
引用
- Alkan A, Carrier ME, Henry RS, et al. Minimal Detectable Changes of the Health Assessment Questionnaire-Disability Index, Patient-Reported Outcomes Measurement Information System-29 Profile Version 2.0 Domains, and Patient Health Questionnaire-8 in People With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Cross-Sectional Study. Arthritis Care Res (Hoboken). 2024. PMID: 38932481. doi:10.1002/acr.25397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。